Tesaro’s ovarian cancer drug gets EU agency backing

(Reuters) – A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.
Original Article

more recommended stories